KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $21.2 million.

  • Esperion Therapeutics' Change in Accured Expenses rose 6322.24% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 2308.07%. This contributed to the annual value of $18.3 million for FY2024, which is 1699.33% down from last year.
  • Esperion Therapeutics' Change in Accured Expenses amounted to $21.2 million in Q3 2025, which was up 6322.24% from -$1.7 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Change in Accured Expenses high stood at $25.0 million for Q1 2021, and its period low was -$21.8 million during Q2 2021.
  • For the 5-year period, Esperion Therapeutics' Change in Accured Expenses averaged around $3.7 million, with its median value being $1.2 million (2022).
  • As far as peak fluctuations go, Esperion Therapeutics' Change in Accured Expenses crashed by 39493.07% in 2021, and later skyrocketed by 69034.06% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Change in Accured Expenses (Quarter) stood at -$789000.0 in 2021, then skyrocketed by 255.77% to $1.2 million in 2022, then surged by 566.8% to $8.2 million in 2023, then decreased by 22.55% to $6.3 million in 2024, then surged by 233.75% to $21.2 million in 2025.
  • Its Change in Accured Expenses stands at $21.2 million for Q3 2025, versus -$1.7 million for Q2 2025 and -$932000.0 for Q1 2025.